Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.55 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 7/20 | 0.50 |
| ▸ | CTSS | P25774 | 6/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6686979 | 0.81 | ATM (0.50) | PPARAPPARGACEPPARDCTSK | |
| SCHEMBL13342853 | 0.81 | PPARA (0.59) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL32672499 | 0.81 | PPARA (0.56) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL29401069 | 0.81 | PPARA (0.59) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL619354 | 0.80 | PPARA (0.61) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL1530926 | 0.80 | PPARA (0.61) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL21084961 | 0.80 | PPARA (0.61) | PPARAPPARGACEPPARDIDO1 | |
| SCHEMBL21473784 | 0.79 | ACE (0.79) | PPARAPPARGACEPPARDCTSK | |
| SCHEMBL795685 | 0.79 | ACE (0.79) | PPARAPPARGACEPPARDCTSK | |
| SCHEMBL66220 | 0.79 | ACE (0.79) | PPARAPPARGACEPPARDCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936606-B2 | Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1434769-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003029200-A2 | COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063679-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | PPARA 4339/4885PPARG 3623/4885ACE 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.